SCHEMBL2889446

SCHEMBL2889446

CC1(C)Oc2cc(N)c(N)cc2C(NCCc2ccccc2)C1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.51
KCNA5 P22460 8/20 0.47
IDO1 P14902 3/20 0.38
ABCC9 O60706 1/20 0.37
FUCA1 P04066 2/20 0.36
NPC1 O15118 1/20 0.36
KDM1A O60341 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
MAOA P21397 1/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007814 1.00 ABCB1 (0.51) ABCB1KCNA5IDO1ABCC9FUCA1
SCHEMBL13476129 0.92 ABCB1 (0.48) ABCB1KCNA5IDO1ABCC9FUCA1
SCHEMBL13476147 0.91 ABCB1 (0.47) ABCB1KCNA5IDO1ABCC9
SCHEMBL13199615 0.91 ABCB1 (0.47) ABCB1KCNA5IDO1ABCC9FUCA1
SCHEMBL2878005 0.88 ABCB1 (0.40) ABCB1KCNA5ABCC9
SCHEMBL2878003 0.88 ABCB1 (0.40) ABCB1KCNA5ABCC9
SCHEMBL13476202 0.88 KCNA5 (0.46) ABCB1KCNA5IDO1ABCC9ALDH1A1
SCHEMBL13476276 0.88 ABCB1 (0.45) ABCB1KCNA5IDO1
SCHEMBL13476163 0.88 ABCB1 (0.55) ABCB1KCNA5ABCC9
SCHEMBL3603668 0.87 ABCB1 (0.52) ABCB1KCNA5IDO1ABCC9FUCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102190661-B Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2013-07-31 CN disclosed
CN-102190661-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD 2011-09-21 CN disclosed
US-7652008-B2 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-26 US disclosed
CN-101429200-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2009-05-13 CN disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed
CN-1934116-A Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2007-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A ABCB1 580/4885KCNA5 67/4885IDO1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.